Loading…
A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study
Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week b...
Saved in:
| Published in: | Investigational new drugs 1995-01, Vol.13 (2), p.171-174 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c241t-e4b3811dcd129f33f32df373fd8999dc214889a0509b11ce1efb5b506dadf3883 |
| container_end_page | 174 |
| container_issue | 2 |
| container_start_page | 171 |
| container_title | Investigational new drugs |
| container_volume | 13 |
| creator | Gradishar, W J Vogelzang, N J Kilton, L J Leibach, S J Rademaker, A W French, S Benson, 3rd, A B |
| description | Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma. |
| doi_str_mv | 10.1007/BF00872868 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00872868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8617582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-e4b3811dcd129f33f32df373fd8999dc214889a0509b11ce1efb5b506dadf3883</originalsourceid><addsrcrecordid>eNpFkEtLAzEYRYMotVY37oWshan5JjN5LOtgdaDgQl0PmTxodB4lSRf9905pUbjcuzncxUHoHsgSCOFPz2tCBM8FExdoDiWnGWEFu0RzAoxnTEp-jW5i_CaEUMmLGZoJBrwU-Rz9rPBuq6LFdY115wevVYdT8FOPDlu99cPYH7Qf8JTeJhWTSl7jOLqEk49xb3FUQY-9WuLVgOtuOhl9xJUatA24skOa5iPtzeEWXTnVRXt33gX6Wr98Vm_Z5v21rlabTOcFpMwWLRUARhvIpaPU0dw4yqkzQkppdA6FEFKRksgWQFuwri3bkjCjJk4IukCPp18dxhiDdc0u-F6FQwOkOQpr_oVN8MMJ3u3b3po_9GyI_gKH8mXk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study</title><source>Springer Nature - Springer Journals Archive Collection</source><creator>Gradishar, W J ; Vogelzang, N J ; Kilton, L J ; Leibach, S J ; Rademaker, A W ; French, S ; Benson, 3rd, A B</creator><creatorcontrib>Gradishar, W J ; Vogelzang, N J ; Kilton, L J ; Leibach, S J ; Rademaker, A W ; French, S ; Benson, 3rd, A B</creatorcontrib><description>Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF00872868</identifier><identifier>PMID: 8617582</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - adverse effects ; Antibiotics, Antineoplastic - therapeutic use ; Dose-Response Relationship, Drug ; Drug Evaluation ; Drugs, Investigational - administration & dosage ; Drugs, Investigational - adverse effects ; Drugs, Investigational - therapeutic use ; Echinomycin - administration & dosage ; Echinomycin - adverse effects ; Echinomycin - therapeutic use ; Female ; Follow-Up Studies ; Humans ; Infusions, Intravenous ; Longitudinal Studies ; Male ; Middle Aged ; Sarcoma - drug therapy ; Sarcoma - mortality ; Sarcoma - secondary ; Soft Tissue Neoplasms - drug therapy ; Soft Tissue Neoplasms - mortality ; Soft Tissue Neoplasms - pathology</subject><ispartof>Investigational new drugs, 1995-01, Vol.13 (2), p.171-174</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-e4b3811dcd129f33f32df373fd8999dc214889a0509b11ce1efb5b506dadf3883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8617582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gradishar, W J</creatorcontrib><creatorcontrib>Vogelzang, N J</creatorcontrib><creatorcontrib>Kilton, L J</creatorcontrib><creatorcontrib>Leibach, S J</creatorcontrib><creatorcontrib>Rademaker, A W</creatorcontrib><creatorcontrib>French, S</creatorcontrib><creatorcontrib>Benson, 3rd, A B</creatorcontrib><title>A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Evaluation</subject><subject>Drugs, Investigational - administration & dosage</subject><subject>Drugs, Investigational - adverse effects</subject><subject>Drugs, Investigational - therapeutic use</subject><subject>Echinomycin - administration & dosage</subject><subject>Echinomycin - adverse effects</subject><subject>Echinomycin - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - mortality</subject><subject>Sarcoma - secondary</subject><subject>Soft Tissue Neoplasms - drug therapy</subject><subject>Soft Tissue Neoplasms - mortality</subject><subject>Soft Tissue Neoplasms - pathology</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNpFkEtLAzEYRYMotVY37oWshan5JjN5LOtgdaDgQl0PmTxodB4lSRf9905pUbjcuzncxUHoHsgSCOFPz2tCBM8FExdoDiWnGWEFu0RzAoxnTEp-jW5i_CaEUMmLGZoJBrwU-Rz9rPBuq6LFdY115wevVYdT8FOPDlu99cPYH7Qf8JTeJhWTSl7jOLqEk49xb3FUQY-9WuLVgOtuOhl9xJUatA24skOa5iPtzeEWXTnVRXt33gX6Wr98Vm_Z5v21rlabTOcFpMwWLRUARhvIpaPU0dw4yqkzQkppdA6FEFKRksgWQFuwri3bkjCjJk4IukCPp18dxhiDdc0u-F6FQwOkOQpr_oVN8MMJ3u3b3po_9GyI_gKH8mXk</recordid><startdate>19950101</startdate><enddate>19950101</enddate><creator>Gradishar, W J</creator><creator>Vogelzang, N J</creator><creator>Kilton, L J</creator><creator>Leibach, S J</creator><creator>Rademaker, A W</creator><creator>French, S</creator><creator>Benson, 3rd, A B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19950101</creationdate><title>A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study</title><author>Gradishar, W J ; Vogelzang, N J ; Kilton, L J ; Leibach, S J ; Rademaker, A W ; French, S ; Benson, 3rd, A B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-e4b3811dcd129f33f32df373fd8999dc214889a0509b11ce1efb5b506dadf3883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Evaluation</topic><topic>Drugs, Investigational - administration & dosage</topic><topic>Drugs, Investigational - adverse effects</topic><topic>Drugs, Investigational - therapeutic use</topic><topic>Echinomycin - administration & dosage</topic><topic>Echinomycin - adverse effects</topic><topic>Echinomycin - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - mortality</topic><topic>Sarcoma - secondary</topic><topic>Soft Tissue Neoplasms - drug therapy</topic><topic>Soft Tissue Neoplasms - mortality</topic><topic>Soft Tissue Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gradishar, W J</creatorcontrib><creatorcontrib>Vogelzang, N J</creatorcontrib><creatorcontrib>Kilton, L J</creatorcontrib><creatorcontrib>Leibach, S J</creatorcontrib><creatorcontrib>Rademaker, A W</creatorcontrib><creatorcontrib>French, S</creatorcontrib><creatorcontrib>Benson, 3rd, A B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gradishar, W J</au><au>Vogelzang, N J</au><au>Kilton, L J</au><au>Leibach, S J</au><au>Rademaker, A W</au><au>French, S</au><au>Benson, 3rd, A B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1995-01-01</date><risdate>1995</risdate><volume>13</volume><issue>2</issue><spage>171</spage><epage>174</epage><pages>171-174</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><abstract>Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.</abstract><cop>United States</cop><pmid>8617582</pmid><doi>10.1007/BF00872868</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6997 |
| ispartof | Investigational new drugs, 1995-01, Vol.13 (2), p.171-174 |
| issn | 0167-6997 1573-0646 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00872868 |
| source | Springer Nature - Springer Journals Archive Collection |
| subjects | Adult Aged Aged, 80 and over Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - therapeutic use Dose-Response Relationship, Drug Drug Evaluation Drugs, Investigational - administration & dosage Drugs, Investigational - adverse effects Drugs, Investigational - therapeutic use Echinomycin - administration & dosage Echinomycin - adverse effects Echinomycin - therapeutic use Female Follow-Up Studies Humans Infusions, Intravenous Longitudinal Studies Male Middle Aged Sarcoma - drug therapy Sarcoma - mortality Sarcoma - secondary Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - mortality Soft Tissue Neoplasms - pathology |
| title | A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A33%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20clinical%20trial%20of%20echinomycin%20in%20metastatic%20soft%20tissue%20sarcoma.%20An%20Illinois%20Cancer%20Center%20Study&rft.jtitle=Investigational%20new%20drugs&rft.au=Gradishar,%20W%20J&rft.date=1995-01-01&rft.volume=13&rft.issue=2&rft.spage=171&rft.epage=174&rft.pages=171-174&rft.issn=0167-6997&rft.eissn=1573-0646&rft_id=info:doi/10.1007/BF00872868&rft_dat=%3Cpubmed_cross%3E8617582%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c241t-e4b3811dcd129f33f32df373fd8999dc214889a0509b11ce1efb5b506dadf3883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/8617582&rfr_iscdi=true |